Literature DB >> 17339492

Relevance of C1 and C2 epitopes for hemopoietic stem cell transplantation: role for sequential acquisition of HLA-C-specific inhibitory killer Ig-like receptor.

Johannes C Fischer1, Hellmut Ottinger, Stanislav Ferencik, Martina Sribar, Michael Punzel, Dietrich W Beelen, M Alexander Schwan, Hans Grosse-Wilde, Peter Wernet, Markus Uhrberg.   

Abstract

Killer Ig-like receptors (KIR) and HLA class I ligands were studied in unrelated hemopoietic stem cell transplantation for chronic myeloid leukemia (n = 108). Significantly improved overall survival was observed in patients, which were homozygous for HLA-C-encoded group 1 (C1) ligands compared with those with group 2 (C2) ligands. Favorable outcome in the former patient group was an early effect that was highly significant in patients transplanted with G-CSF-mobilized peripheral blood and patients with advanced disease stages. In contrast, presence of C1 ligands in the donor was associated with significantly reduced patient survival. The differential roles of the two HLA-C ligands are explained in the context of a biased NK cell reconstitution, which is generally dominated by the presence of C1- but absence of C2-specific NK cells. The clinical observations are corroborated by in vitro experiments showing that NK cells derived from hemopoietic progenitor cells generally acquire the C1-specific inhibitory KIR2DL2/3 at earlier time points and with higher frequency than the C2-specific KIR2DL1. These findings define a novel determinant for understanding the role of NK cells in clinical hemopoietic stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17339492     DOI: 10.4049/jimmunol.178.6.3918

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHC.

Authors:  Isabel Barao; Maite Alvarez; Erik Ames; Mark T Orr; Heather E Stefanski; Bruce R Blazar; Lewis L Lanier; Stephen K Anderson; Doug Redelman; William J Murphy
Journal:  Blood       Date:  2011-04-15       Impact factor: 22.113

2.  T cell subset-specific susceptibility to aging.

Authors:  Marta Czesnikiewicz-Guzik; Won-Woo Lee; Dapeng Cui; Yuko Hiruma; David L Lamar; Zhi-Zhang Yang; Joseph G Ouslander; Cornelia M Weyand; Jörg J Goronzy
Journal:  Clin Immunol       Date:  2008-01-28       Impact factor: 3.969

3.  Permanent silencing of NKG2A expression for cell-based therapeutics.

Authors:  Constança Figueiredo; Axel Seltsam; Rainer Blasczyk
Journal:  J Mol Med (Berl)       Date:  2008-11-11       Impact factor: 4.599

4.  Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes.

Authors:  Maryam Hejazi; Angela R Manser; Julia Fröbel; Andrea Kündgen; Xiaoyi Zhao; Kathrin Schönberg; Ulrich Germing; Rainer Haas; Norbert Gattermann; Markus Uhrberg
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

5.  NK cell development in a human stem cell niche: KIR expression occurs independently of the presence of HLA class I ligands.

Authors:  Xiaoyi Zhao; Sandra Weinhold; Jens Brands; Maryam Hejazi; Özer Degistirici; Gesine Kögler; Roland Meisel; Markus Uhrberg
Journal:  Blood Adv       Date:  2018-10-09

Review 6.  The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer.

Authors:  Frank Cichocki; Michael R Verneris; Sarah Cooley; Veronika Bachanova; Claudio G Brunstein; Bruce R Blazar; John Wagner; Heinrich Schlums; Yenan T Bryceson; Daniel J Weisdorf; Jeffrey S Miller
Journal:  Curr Top Microbiol Immunol       Date:  2016       Impact factor: 4.291

7.  CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells.

Authors:  Juan Du; Sandra Lopez-Verges; Brandelyn N Pitcher; Jeffrey Johnson; Sin-Ho Jung; Lili Zhou; Katharine Hsu; Myron S Czuczman; Bruce Cheson; Lawrence Kaplan; Lewis L Lanier; Jeffrey M Venstrom
Journal:  Cancer Immunol Res       Date:  2014-06-23       Impact factor: 11.151

8.  Recipient HLA-C Haplotypes and microRNA 148a/b Binding Sites Have No Impact on Allogeneic Hematopoietic Cell Transplantation Outcomes.

Authors:  Gretchen A Hoff; Johannes C Fischer; Katharine Hsu; Sarah Cooley; Jeffrey S Miller; Tao Wang; Michael Haagenson; Stephen Spellman; Stephanie J Lee; Markus Uhrberg; Jeffrey M Venstrom; Michael R Verneris
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-13       Impact factor: 5.742

Review 9.  Selected biological issues affecting relapse after stem cell transplantation: role of T-cell impairment, NK cells and intrinsic tumor resistance.

Authors:  Marcel van den Brink; Markus Uhrberg; Lorenz Jahn; John F DiPersio; Michael A Pulsipher
Journal:  Bone Marrow Transplant       Date:  2018-01-24       Impact factor: 5.483

10.  Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation.

Authors:  Junli Yu; Jeffrey M Venstrom; Xiao-Rong Liu; James Pring; Reenat S Hasan; Richard J O'Reilly; Katharine C Hsu
Journal:  Blood       Date:  2009-01-28       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.